This article has been copublished in the April issue of Clinical Chemistry (Volume 53,
Number 4, 2007). 1 Brigham and Women's Hospital, Harvard University, Boston, MA. 2 …

Given the importance of cardiac enzyme elevations in the diagnosis of AMI, 8 attention has
been directed to the development of progressively more accurate biomarkers of myocardial …

Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patients.
The mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood …

Background Management of acute coronary syndromes (ACS) should be guided by an
estimate of patient risk. Objective To develop a simple model to assess the risk for in …

Objective To develop a clinical risk prediction tool for estimating the cumulative six month
risk of death and death or myocardial infarction to facilitate triage and management of …

The management of acute myocardial infarction continues to undergo major changes. Good
practice should be based on sound evidence derived from well-conducted clinical trials …

ContextRandomized trials provide robust evidence for the impact of pharmacological and
interventional treatments in patients with ST-segment elevation and non–ST-segment …

Aims To better delineate the characteristics, treatments, and outcomes of patients with acute
coronary syndromes (ACS) in representative countries across Europe and the …

Acute coronary syndrome (ACS) represents a heterogenous spectrum of conditions. The
Global Registry of Acute Coronary Events (GRACE) describes the epidemiology …

Aims Despite advances in the treatment of acute coronary syndromes based on randomized
trial data and published guidelines, the extent to which such treatments are applied in …